Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Generation Bio Co. - Common stock (NQ:GBIO)

5.468 -0.032 (-0.59%)
Streaming Delayed Price Updated: 10:33 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Generation Bio Co. - Common stock

< Previous 1 2 Next >
Generation Bio Announces CEO Transition
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces 1-for-10 Reverse Stock Split
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Second Quarter 2024 Financial Results
Cash balance of $217 million still expected to fund operations into 2H 2027 
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
From Generation Bio Co.
Via GlobeNewswire
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Generation Bio Co.
Via GlobeNewswire
Generation Bio Reports Second Quarter 2023 Financial Results
Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025 
From Generation Bio Co.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.